As it was reported that mTOR inhibitors, including rapamycin and AZD8055, sensitize SCLC cell lines to ABT-737/263 (refs 25, 33), we compared the death inducing activity of combined ABT-263 and mTOR inhibitors with that of combined ABT-263 and dinaciclib in four ABT-263-resistant SCLC cell lines (Supplementary Fig. 5). Here, MTOR is linked to small cell lung carcinoma.